Follow The Filings

ROIV position history

The shares of Roivant Sciences (ROIV) that DME Capital Management reported in each quarter’s 13F.

Equity, SHS

Shares held by quarter

New Add Reduce Exit

  1. 2024 Q1: 4,190,490 shares, $44M, 2.0% of portfolio
  2. 2024 Q2: 4,810,960 shares, $51M, 2.5% of portfolio, Add +14.8%
  3. 2024 Q3: 5,308,040 shares, $61M, 2.5% of portfolio, Add +10.3%
  4. 2024 Q4: 5,271,067 shares, $62M, 3.2% of portfolio, Reduce −0.7%
  5. 2025 Q1: 5,441,167 shares, $55M, 2.8% of portfolio, Add +3.2%
  6. 2025 Q2: 4,551,057 shares, $51M, 2.2% of portfolio, Reduce −16.4%
  7. 2025 Q3: 2,275,529 shares, $34M, 1.4% of portfolio, Reduce −50.0%
  8. 2025 Q4: 2,069,309 shares, $45M, 1.6% of portfolio, Reduce −9.1%
  9. 2026 Q1: 2,152,669 shares, $60M, 1.9% of portfolio, Add +4.0%
  10. 2026 Q2: 2,152,669 shares, $76M, 1.9% of portfolio
  11. 2026 Q3: 1,131,747 shares, $41M, 1.2% of portfolio, Reduce −47.4%
Holdings date Value % of holdings Shares Filing date All 13F holders